100 days with John Crowley: Behind BIO’s new structure & vision
Jun 25, 2024 · With only a little more than 100 days at the helm, BIO CEO John Crowley has already implemented a restructure and taken a stance on U.S. biosecurity.
He Designed Drugs to Save His Children. Now He’s Working to …
Dec 5, 2023 · Nearly a quarter-century after plunging into biotech to find drugs to save Megan and her younger brother, Patrick, from a rare and deadly genetic disease, Crowley feared the battle had suddenly...
John Crowley (businessman) - Wikipedia
John Francis Crowley (born April 7, 1967) is the President and CEO of the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology advocacy organization. [1] He served as the chairman and CEO of Amicus Therapeutics.
He Designed Drugs to Save His Children. Now He’s Working to ... - MSN
The Wall Street Journal chronicled the early years of Crowley’s work on the first drug, which he credits with fixing his children’s hearts, the most life-threatening aspect of the disease.
John F. Crowley - BIO
The wait is finally over as the Biotechnology Innovation Organization (BIO) taps John F. Crowley, a longtime leader and tireless patient advocate in the biotech industry, to fill the role of the organization’s new CEO.
John F. Crowley at GEN State of Biotechnology 2024 - Bio.News
Sep 13, 2024 · John F. Crowley, President & CEO of the Biotechnology Innovation Organization (BIO), gave a keynote about BIO’s work, how the current political landscape is affecting the industry, the Inflation Reduction Act (IRA), the BIOSECURE Act, and much more.
BIO names longtime Amicus head John Crowley as new CEO
Dec 5, 2023 · The Biotech Innovation Organization on Tuesday named Amicus Therapeutics co-founder and longtime leader John Crowley as its new CEO, taking over a spot interim chief Rachel King has held for the past 14 months.
New Pompe disease treatment 'exciting,' Amicus chairman says
Nov 9, 2023 · Bringing a third medication for late-onset Pompe disease (LOPD) to the treatment table is a personal triumph for Amicus Therapeutics executive chairman John Crowley.
Industry Leader and Globally Recognized Patient Advocate John F …
Dec 5, 2023 · Biotech entrepreneur, company founder, tireless patient advocate, and U.S. Navy combat veteran will guide the life science industry in its mission to feed, fuel and heal the world.
Amicus Leader, BIO Board Member John Crowley Named Trade ... - MedCity News
Dec 5, 2023 · John Crowley, the longtime leader of rare disease drug developer Amicus Therapeutics and a board member of the Biotechnology Innovation Organization, will become the trade organization’s new...
- Some results have been removed